AVEO Pharmaceuticals, Staar Surgical, Vericel, PDL BioPharma, Natural Alternatives top the NASDAQ biotech stock list.
Friday Night Inc. (the “Company”) (CSE:TGIF) (FRANKFURT:1QF) is pleased to announce that the Company has appointed Dr. Anthony R. Torres, MD to its board of advisors and would also like to provide an update on the genetics breeding program at the Company’s 91% owned subsidiary, Alternative Medicine Association, LC. (AMA).
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership with the genetics company.
Atossa Genetics completed enrollment for their Phase 1 dose escalation study of Atossa’s proprietary Endoxifen.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
Rennova decided to spin off its genetic division and create a brand new, publicly traded company, INN interviews the CEO of this game changing genetic testing company.
Abeona Therapeutics is on the path to speed up its EB-101 gene therapy interventional study to a Phase 3 clinical trial.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
Interleukin Genetics decided to fire 63 percent of their workforce, five employees, in an effort to “preserve capital” as it begins looking for alternative strategies for the company.
Atossa Genetics shared a batch of positive interim safety data from its Phase 1 dose escalation study on Endoxifen.